Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma
Recruiting
N/A
Interventional Study
Hepatocellular Carcinoma Non-resectable
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 30 (estimated)
- Sponsor
- RWTH Aachen University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The study investigates the adjuvant SBRT following TACE in early and intermediate stages HCC not amenable for surgical resection.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* HCC (diagnosis: histological or radiological)
* Age: 18-80
* Number of lesions 1-3 lesions
* Size of the lesion (or sum of 2-3 lesions) ≥ 4 cm
* Sufficient non-tumorous liver volume (≥ 800 cm3)
* Child Pugh Score: A5-6 or B7-8
* BCLC A or B
* Patient is illegible or refused su…
Contacts